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Background: Clozapine is the recommended antipsychotic for treatment-resistant
schizophrenia (TRS) but there is significant variability between patients in the degree to
which clozapine will improve symptoms. The biological basis of this variability is unknown.
Although clozapine has efficacy in TRS, it can elicit adverse effects and initiation is often
delayed. Identification of predictive biomarkers of clozapine response may aid initiation of
clozapine treatment, as well as understanding of its mechanism of action. In this article we
systematically review prospective or genetic studies of biological predictors of response
to clozapine.
Methods: We searched the PubMed database until 20th January 2018 for
studies investigating “clozapine” AND (“response” OR “outcome”) AND “schizophrenia.”
Inclusion required that studies examined a biological variable in relation to symptomatic
response to clozapine. For all studies except genetic-studies, inclusion required that
biological variables were measured before clozapine initiation.
Results: Ninety-eight studies met the eligibility criteria and were included in the review,
including neuroimaging, blood-based, cerebrospinal fluid (CSF)-based, and genetic
predictors. The majority (70) are genetic studies, collectively investigating 379 different
gene variants, however only three genetic variants (DRD3 Ser9Gly, HTR2A His452Tyr,
and C825T GNB3) have independently replicated significant findings. Of the non-genetic
variables, the most consistent predictors of a good response to clozapine are higher
prefrontal cortical structural integrity and activity, and a lower ratio of the dopamine and
serotonin metabolites, homovanillic acid (HVA): 5-hydroxyindoleacetic acid (5-HIAA) in
CSF.
Conclusions: Recommendations include that future studies should ensure adequate
clozapine trial length and clozapine plasma concentrations, and may include multivariate
models to increase predictive accuracy.
Keywords: clozapine, treatment response, schizophrenia, treatment-resistance, response biomarker
INTRODUCTION
Approximately one third of patients with schizophrenia do not respond to standard
antipsychotic treatment and are classified as having treatment resistant schizophrenia (TRS)
(1). Clozapine has efficacy in reducing symptoms in patients who have not responded to other
antipsychotics (2–4), but carries risk of serious side effects and requires regular blood monitoring.
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Unfortunately, clozapine will still fail to improve symptoms in
40 to 70% of TRS patients (2, 5), and currently this can only
be determined through a trial of clozapine treatment. For these
reasons patients and clinicians are often reluctant to initiate
clozapine treatment. For example, a recent study found that
there was a delay of around 4 years between patients meeting
TRS criteria and the initiation of clozapine, and that during this
period patients were often treated with alternative drug regimens
that are not evidence-based and are associated with adverse
effects, such as antipsychotics at doses higher than the maximum
recommended, and antipsychotic polypharmacy (6). If tests
could be developed to help clinicians predict in advance whether
or not a given patient is likely to respond to clozapine, this could
substantially reduce the delay before clozapine initiation, and
clozapine could be selectively employed in the subset of patients
in whom it is likely to be effective.
Of course, clozapine response first requires adequate dosing;
patients who have clozapine plasma concentrations of 350 ng/mL
or above are more likely to show improvements in symptoms,
with reported sensitivity and specificity of 64–86 and 55–
78% (7–10). Nonetheless a significant proportion of patients
do not improve despite having adequate clozapine plasma
concentrations (9), which may be termed “clozapine resistant
schizophrenia” (11). An emerging number of cross-sectional
studies that have compared treatment-resistant to treatment
responsive schizophrenia report biological differences at group
level, which may suggest that TRS is a categorically distinct
illness subtype (12), and it is possible that clozapine-resistant
schizophrenia may reflect a further biological subtype. Overall,
this suggests that individual biological variability may play an
important role in determining the degree of clozapine response
in the context of adequate dosing. This raises the possibility that
biological markers may be able to predict the likelihood that
symptoms will improve with clozapine treatment in advance of
clozapine initiation.
Numerous studies have investigated biological predictors
of response to non-clozapine antipsychotics, including
symptomatic response to initial antipsychotic administration
in patients with first-episode psychosis [for recent review see
(13)]. The degree of antipsychotic response may be related to
brain structure (14), neurochemistry (15), or activity (16–19)
before starting antipsychotic treatment, or associated with
genetic variability (20). However, it is unknown whether similar
factors may be predictive of response to clozapine, and this
is a particularly important question for clinical practice as it
Abbreviations: ACTH, adrenocorticotropic hormone; BPRS, brief psychiatric
rating Scale; CGI, clinical global impression; CSF, cerebrospinal fluid; CT,
computerized tomography; DLPFC, dorsolateral prefrontal cortex; ECG,
electrocardiogram; EEG, electroencephalogram; GWAS, genome-wide association
studies; HLA, human leukocyte antigen; 5-HIAA, ty5-hydroxyindoleacetic
acid; HVA, homovanillic acid; MAO-B, monoamine oxidase B; MCPP, m-
chlorophenylpiperazine; MHPG, 3-methoxy-4-hydroxyphenylglycol; MRI,
magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NAA,
n-acetyl aspartate; NMDA, N-methyl-D-aspartate; PANSS, positive and negative
syndrome scale; PET, positron emission tomography; SANS, scale for the
assessment of negative symptoms; SAPS, scale for the assessment of positive
Symptoms; SNPs, single nucleotide polymorphisms; SPECT, single photon
emission computerized tomography; TRS, treatment resistant schizophrenia.
may encourage earlier clozapine initiation in those patients
most likely to benefit, or avoidance of clozapine exposure in
those unlikely to respond. Recent studies indicate that there
are two distinct patterns of treatment-resistance onset, with
some patients developing resistance later in their illness but the
majority demonstrating resistance from illness onset (21, 22),
further supporting the need to promptly identify these patients
and establish their likelihood of responding to clozapine.
The purpose of this article is to provide a systematic
review of studies that have investigated biological predictors
of response to clozapine, in order to provide an update on
the research in the area and identify the most promising areas
for further investigation. We limit our scope to biological
variables as predictors of response. Demographic and clinical
factors may also be important in understanding some aspects
of clozapine response, and these have been comprehensively
reviewed elsewhere (23, 24).
METHODS
Search Strategy
The search was performed in the PubMed database on 20th
January 2018 using the keywords “clozapine” AND (“response”
OR “outcome”) AND “schizophrenia.” The search was limited to
the titles and abstracts of the papers, with additional filters set to
human studies and English language.
Abstracts were reviewed against study inclusion and exclusion
criteria (below), and independently reviewed; there was an inter-
rater reliability kappa of 0.914. The full text of the remaining
potentially eligible studies were reviewed independently by
authors RS and AG; there was 100% agreement on inclusion of
the final studies. Reference lists were hand-searched to identify
additional studies.
Study Selection
Inclusion required that studies were published in English in
peer-reviewed academic journals. Inclusion also required that
studies examined a biological variable in relation to clozapine
response. Only studies that measured clozapine response as
a change in positive, negative or overall symptom severity
or global functioning were included. For biological variables
such as brain activity or metabolite concentrations in blood,
which may be affected by clozapine treatment, inclusion
required that these measures were acquired prospectively,
before clozapine initiation. For genetic variables, cross-sectional
studies of clozapine response were also included. Studies were
included if they investigated either clozapine monotherapy or
clozapine in combination with other pharmacological or non-
pharmacological interventions, as is reflective of clinical practice.
Data reported only in editorials, review articles, conference
abstracts, conference reports, news articles, meta-analyses, or
other non-primary data formats were excluded. Where more
than one article reported data in overlapping patient samples,
only the study with the largest sample was included. Studies were
also excluded if the samples included a combination of patients
taking only non-clozapine antipsychotics and clozapine-treated
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patients, without reporting results for clozapine-treated patients
separately.
Data Extraction
Data were extracted into an Excel database. The following data
were extracted: the biological predictor variable(s), sample size,
availability of plasma clozapine concentrations (yes/no), mean
plasma clozapine concentrations, mean clozapine dose, duration
of clozapine treatment (months), the clozapine response criteria
used, and whether results were statistically significant.
For review, articles were categorized into neuroimaging,
blood-based, cerebrospinal fluid-based, cardiac, and genetic
markers.
RESULTS
The search returned 753 articles. Abstract review identified 126
potentially eligible studies, and subsequent full-text screening
identified 69 eligible studies. The excluded studies are listed in
Table 1. Twenty-nine additional eligible articles were identified
via other means including hand-searches of reference lists
(Figure 1).
Study Characteristics
Ninety-eight studies met the inclusion criteria, for which the
methodological details are provided in Tables 2, 4, 6, and 8.
Of these, 70 studies investigated genetic variables, 16 studies
investigated blood or CSF-based variables, 11 studies investigated
neuroimaging markers, and 1 investigated a cardiac variable.
Sample sizes ranged from 7 (42) to 591 participants (43). Studies
included participants from across Europe (Britain, Turkey, Italy,
Spain, Germany), America, Canada, and Asia (China, Israel,
India, Taiwan, Pakistan).
As detailed in Tables 2, 4, 6, and 8, clozapine trial length
varied from 4 weeks (44) to 16 months (45). Only nine studies
(9%) reported clozapine plasma levels; of these, six gave a group
mean (46–51) and three reported the mean dose for a responder
and non-responder group separately (52–54). Sixty-three studies
(64%) reported data on clozapine doses. Of these, 21 reported the
dose range across the sample (e.g., 150–600mg) while 36 reported
the group mean and 6 reported the mean dose for a responder
and non-responder group separately.
The primary outcome variables for determining clozapine
response varied considerably (Tables 2, 4, 6, and 8). Thirteen
studies used a combination of outcome measures to define
clozapine response, and one used different outcome measures for
different participants (55).
Neuroimaging Predictors of Clozapine
Response
Eleven neuroimaging studies met the inclusion criteria
(Tables 2, 3). These included four structural imaging studies,
three single photon emission computerized tomography
or positron emission tomography (SPECT/PET) studies
of brain perfusion or metabolism, one proton magnetic
resonance spectroscopy (1H-MRS) study of brain metabolite
concentrations, and five electro-encephalography (EEG) studies.
The length of clozapine treatment in the neuroimaging studies
ranged from 4 weeks (33) to 1 year (37, 38), but none reported
plasma clozapine levels.
Brain Structure
The first published study used computerized tomography (CT)
to examine sulcal widening as a predictor of clozapine response
(36). A good clozapine response was associated with significantly
lower widening scores in the prefrontal sulci compared to a
poor response, suggesting that poor clozapine response may
be associated with a higher degree of frontal atrophy. Three
more recent studies used structural magnetic resonance imaging
(MRI) to predict clozapine response. In a clinical trial of
clozapine vs. haloperidol, Arango et al. (31) found that larger
right prefrontal cortical gray matter volumes were associated
with greater reduction in SANS total scores after treatment
in the clozapine group. No associations were found with
positive symptoms, or for relationships between symptoms and
caudate, hippocampal or total intracranial volumes. Molina et al.
(37) investigated associations between regional brain volume
and clozapine response. Temporal cortex volume was directly
associated with improvement in positive symptoms, whereas
dorsolateral prefrontal cortical (DLPFC) cerebrospinal fluid
(CSF) content was inversely associated with improvement in
positive symptoms. DLPFC volume was directly associated with
improvement in negative symptom severity, and the intracranial
volume was negatively related to improvement in disorganization
syndrome.
These studies therefore provide a generally consistent
picture that greater volumes, particularly in frontal
cortical regions, are associated with a better response to
clozapine treatment. However, Molina et al. (38) found
that thinner baseline right pars orbitalis cortex predicted
greater improvement in PANSS scores following at least
1 year clozapine use in antipsychotic-naïve first-episode
patients. This difference might be explained by the different
patient populations, with the two former studies including
treatment-resistant patients with previous antipsychotic
exposure and the latter including antipsychotic-naïve
patients who may have responded to conventional
antipsychotics.
Brain Perfusion and Metabolism
Regional brain perfusion and metabolism were also investigated
as predictors of clozapine response. Rodriguez et al. (41), in
an extension of an earlier report (56), used 99mTc-HMPAO
single photon emission computed tomography (SPECT) to
measure regional brain perfusion as a predictor of response to
clozapine. Compared to the non-responder group, responders
had higher baseline perfusion in right lower DLPFC, left upper
DLPFC, thalamus, and left and right basal ganglia. Discriminant
analysis showed that perfusion in the thalamus and right DLPFC
distinguished between responders and non-responders with
78.9% accuracy. Similarly, Ertugrul et al. (32), also employing
Tc-99m HMPAO SPECT imaging, reported that increased levels
of perfusion in the right frontal cortex and thalamus were
associated with greater improvement in PANSS score with
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TABLE 1 | Excluded studies.
First Author, Year Title Exclusion reason
(25) Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after
Commencing Clozapine Treatment.
Compares longitudinal changes after initiation
not baseline variation
Ajami, 2014 Changes in serum levels of brain derived neurotrophic factor and nerve
growth factor-beta in schizophrenic patients before and after treatment.
Results include non-clozapine medication
Blessing, 2011 Atypical antipsychotics cause an acute increase in cutaneous hand blood
flow in patients with schizophrenia and schizoaffective disorder.
On clozapine at baseline
Buchsbaum, 1992 Effects of clozapine and thiothixene on glucose metabolic rate in
schizophrenia.
Cannot obtain full-text to confirm
Curtis, 1995 Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in
schizophrenia and its relationship to clinical improvement.
Compares longitudinal changes after initiation
not baseline variation
Delieu, 2001 Antipsychotic drugs result in the formation of immature neutrophil
leucocytes in schizophrenic patients.
Does not measure outcome
Dursun, 1999 The effects of clozapine on levels of total cholesterol and related lipids in
serum of patients with schizophrenia: a prospective study.
Does not report results for response
(26) The effect of clozapine on neuroimaging findings in schizophrenia. Cannot obtain full-text to confirm
Frieboes, 1999 Characterization of the sigma ligand panamesine, a potential antipsychotic,
by immune response in patients with schizophrenia and by sleep-EEG
changes in normal controls.
Does not investigate clozapine
(27) Prefrontal sulcal prominence is inversely related to response to clozapine in
schizophrenia.
Does not specify when biological variable
measured
Ghaleiha, 2011 Correlation of adenosinergic activity with superior efficacy of clozapine for
treatment of chronic schizophrenia: a double blind randomized trial.
Compares biological variable after initiation
Gothelf, 1999 Clinical characteristics of schizophrenia associated with velo-cardio-facial
syndrome.
No variation in biological variable
Gothert, 1998 Genetic variation in human 5-HT receptors: potential pathogenetic and
pharmacological role.
Not primary research - review
Graff-Guerrero, 2009 The effect of antipsychotics on the high-affinity state of D2 and D3
receptors: a positron emission tomography study With [11C]-(+)-PHNO.
Cross-sectional
Gross, 2004 Clozapine-induced QEEG changes correlate with clinical response in
schizophrenic patients: a prospective, longitudinal study.
Compares longitudinal changes after initiation
not baseline variation
(28) Regional cortical anatomy and clozapine response in refractory
schizophrenia.
Does not specify when biological variable
measured
Hsu, 2000 No evidence for association of alpha 1a adrenoceptor gene polymorphism
and clozapine-induced urinary incontinence.
Outcome not therapeutic response
Jacobsen, 1997 Cerebrospinal fluid monoamine metabolites in childhood-onset
schizophrenia.
Compares longitudinal changes after initiation
not baseline variation
Jenkins, 2014 Identification of candidate single-nucleotide polymorphisms in NRXN1
related to antipsychotic treatment response in patients with schizophrenia.
Does not investigate clozapine
Jones, 1998 Neuroendocrine evidence that clozapine’s serotonergic antagonism is
relevant to its efficacy in treating hallucinations and other positive
schizophrenic symptoms.
Does not specify when biological variable
measured
Joober, 1999 T102C polymorphism in the 5HT2A gene and schizophrenia: relation to
phenotype and drug response variability.
Does not investigate clozapine
Knott, 2001 Quantitative EEG in schizophrenia and in response to acute and chronic
clozapine treatment.
Does not report results for response
Knott, 2002 EEG coherence following acute and chronic clozapine in treatment-resistant
schizophrenics.
Overlapping sample with other study
Lahdelma, 1998 Association between HLA-A1 allele and schizophrenia gene(s) in patients
refractory to conventional neuroleptics but responsive to clozapine
medication.
Does not measure outcome
Lahdelma, 2001 Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good
therapeutic response to clozapine with a low risk of agranulocytosis in
patients with schizophrenia.
No clozapine non-responders
(29) Clozapine but not haloperidol Re-establishes normal task-activated rCBF
patterns in schizophrenia within the anterior cingulate cortex.
Does not report results for response
Lally, 2013 Increases in triglyceride levels are associated with clinical response to
clozapine treatment.
Compares longitudinal changes after initiation
not baseline variation
(Continued)
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TABLE 1 | Continued
First Author, Year Title Exclusion reason
Lauriello, 1998 Association between regional brain volumes and clozapine response in
schizophrenia.
Compares biological variable after initiation
Machielsen, 2014 The effect of clozapine and risperidone on attentional bias in patients with
schizophrenia and a cannabis use disorder: An fMRI study.
Does not report results for response
Maes, 1997 In vivo immunomodulatory effects of clozapine in schizophrenia. Does not specify when biological variable
measured
Maes, 2002 Increased serum interleukin-8 and interleukin-10 in schizophrenic patients
resistant to treatment with neuroleptics and the stimulatory effects of
clozapine on serum leukemia inhibitory factor receptor.
Does not specify when biological variable
measured
Malow, 1994 Spectrum of EEG abnormalities during clozapine treatment. Does not measure outcome
Markianos, 1999 Switch from neuroleptics to clozapine does not influence pituitary-gonadal
axis hormone levels in male schizophrenic patients.
Compares longitudinal changes after initiation
not baseline variation
Meltzer, 1993 The cimetidine-induced increase in prolactin secretion in schizophrenia:
effect of clozapine.
Does not measure outcome
Molina, 2008 Clozapine may partially compensate for task-related brain perfusion
abnormalities in risperidone-resistant schizophrenia patients.
Compares longitudinal changes after initiation
not baseline variation
Monteleone, 2004 Long-term treatment with clozapine does not affect morning circulating
levels of allopregnanolone and THDOC in patients with schizophrenia: a
preliminary study.
Does not report results for response
Mouaffak, 2011 Association of an UCP4 (SLC25A27) haplotype with ultra-resistant
schizophrenia.
Results include non-clozapine medication
(30) The SNAP-25 gene may be associated with clinical response and weight
gain in antipsychotic treatment of schizophrenia.
Results include non-clozapine medication
Murad, 2001 A family-based study of the Cys23Ser 5HT2C serotonin receptor
polymorphism in schizophrenia.
Does not measure outcome
Niznikiewicz, 2005 Clozapine action on auditory P3 response in schizophrenia. Does not measure outcome
Ozdemir, 2001 Treatment-resistance to clozapine in association with ultrarapid CYP1A2
activity and the C–>A polymorphism in intron 1 of the CYP1A2 gene: effect
of grapefruit juice and low-dose fluvoxamine.
Individual case report
Patel, 1997 Chronic schizophrenia: response to clozapine, risperidone, and paroxetine. Individual case report
Paunovia, 1991 Neuroleptic actions on the thyroid axis: different effects of clozapine and
haloperidol.
Does not measure outcome
Pedrini, 2011 Serum brain-derived neurotrophic factor and clozapine daily dose in
patients with schizophrenia: a positive correlation.
Does not report results for response
Peet, 2002 A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate
in patients with persistent schizophrenic symptoms.
Does not report results for response
Pickar, 1994 Clinical response to clozapine in patients with schizophrenia. Does not investigate clozapine
Pilowsky, 1992 Clozapine, single photon emission tomography, and the D2 dopamine
receptor blockade hypothesis of schizophrenia.
Does not report results for response
Procyshyn, 2007 Changes in serum lipids, independent of weight, are associated with
changes in symptoms during long-term clozapine treatment.
Results include non-clozapine medication
Reynolds, 1996 The importance of dopamine D4 receptors in the action and development of
antipsychotic agents.
Not primary research - review
Risby, 1995 Clozapine-induced EEG abnormalities and clinical response to clozapine. No variation in biological variable
Ruderfer, 2016 Polygenic overlap between schizophrenia risk and antipsychotic response:
a genomic medicine approach.
Does not measure outcome
Schulz, 1997 Blood biogenic amines during clozapine treatment of early-onset
schizophrenia.
Overlapping sample with other study
Sun 2016 Diurnal neurobiological alterations after exposure to clozapine in
first-episode schizophrenia patients.
Does not report results for response
Swerdlow, 2006 Antipsychotic effects on prepulse inhibition in normal ’low gating’ humans
and rats.
Does not investigate clozapine
Szekeres, 2004 Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT)
polymorphism in cognitive dysfunctions and therapeutic response to
atypical antipsychotics in patients with schizophrenia.
Results include non-clozapine medication
Treves, 1996 EEG abnormalities in clozapine-treated schizophrenic patients. Compares biological variable after initiation
Zahn, 1993 Autonomic effects of clozapine in schizophrenia: comparison with placebo
and fluphenazine.
Does not specify when biological variable
measured
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FIGURE 1 | PRISMA diagram.
clozapine treatment. Molina et al. (37), using 18F-deoxyglucose
(18F-DG) positron emission tomography (PET), found that
baseline metabolic rate in the DLPFC was directly related to
improvement in negative symptoms, however no associations
were found between metabolism in other brain regions, or with
improvement in positive or disorganization symptoms. This
finding of a direct association between DLPFC metabolic rate
and clozapine response is consistent with findings of a direct
association between DLPFC perfusion and clozapine response
(32, 41).
Magnetic Resonance Spectroscopy
One 1H-MRS study investigated whether metabolite
concentrations in the DLPFC may predict response to
clozapine (32). In this sample of 22 patients, neither the
concentration of n-acetyl aspartate (NAA) nor choline was
predictive of the subsequent degree of change in symptoms
on the PANSS. Relationships with other metabolites in
the 1H-MRS spectrum, including glutamate, were not
reported.
Electroencephalography
Five EEG studies, investigating a range of variables related
to brain electrical activity, including EEG abnormalities and
hemispheric asymmetry, were included (33–35, 39, 40). The
first EEG study (39) investigated whether clozapine response
was predicted by the presence of minor EEG abnormalities,
defined as focal or generalized slowing or sharp waves, focal
dysrhythmias, spikes, and spike-wave patterns. There were no
overall differences in clozapine response between patients with
normal compared to abnormal EEG, however secondary analysis
found that in female participants, improvements in GAF score
were greater in those with a normal EEG before clozapine
treatment. Knott et al. (35) reported that improvements in
PANSS positive, negative symptoms and global psychopathology
were related to greater intrahemispheric frequency asymmetries.
Kang et al. (33) ran mutual cross-prediction analysis to identify
if activity in one channel was driving the dynamics of another
channel. The sample was too small to conduct significant testing,
but they observed that the group of participants without a
frontal-driving system and occipital response system had a higher
proportion of responders to clozapine. A fourth EEG study of
clozapine response (34) applied a machine-learning algorithm to
distinguish clozapine responders and non-responders based on
their pre-treatment EEG measures, using first the leave-one-out
cross-validation procedure and then two independent datasets
to train and test the classifiers. This algorithm successfully
distinguished these groups with more than 85% accuracy. The
authors reported a list of 20 EEG measures that were found
to have the greatest predictive value, which mainly included
measures of the left temporal areas. Similarly, Ravan et al.
(40) applied a machine-learning algorithm to patients’ EEG
data from before and after a year of clozapine treatment.
The most-responsive patients had five “discriminating features”
at baseline; these were predominantly in the beta-band,
with the most dominant features joint activity between the
pre-frontal and right parietal or right anterior temporal
regions.
CSF-Based Predictors of Clozapine
Response
A priori selection of CSF- and peripheral predictive biomarkers
of clozapine response has been driven by clozapine’s “atypical”
pharmacological profile of high affinity at serotonin 5-HT2A
receptors in combination with lower affinity at dopamine
D2 receptors (57). Our search returned three studies of CSF
biochemicals in predicting clozapine response (Tables 4, 5).
Two of these studies provided data on plasma clozapine
concentrations (47, 48). Sample sizes in these studies ranged from
10 (64) to 21 participants (47), and all used the BPRS to measure
symptomatic improvement.
CSF Monoamines
All three studies investigated the dopamine metabolite
homovanillic acid (HVA), and the serotonin metabolite 5-
hydroxyindoleacetic acid (5-HIAA) (47, 48, 64). None of these
studies found that HVA nor 5-HIAA concentrations alone were
predictive of clozapine response. The ratio between HVA and
5-HIAA was also investigated. In all studies, lower HVA/5-HIAA
concentration ratios before clozapine were associated with
a greater degree of subsequent symptomatic improvement,
both in the short- and longer-term (47, 48, 64). This suggests
that the balance between dopamine and serotonin metabolism
before clozapine administration may be predictive of clozapine
response, with lower levels of dopamine metabolism relative
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TABLE 2 | Included neuroimaging studies.
Study Imaging variables Participant
sample
Minimum
clozapine
trial
Outcome measure Clozapine dose Plasma
clozapine
(31) MRI (caudate, prefrontal cortex,
hippocampal volume)
17 White
American
5 African
American
10 weeks BPRS, SANS 200–600mg Not
reported
(32) SPECT and MRS (frontal, parietal,
temporal, and occipital lobes, the caudate,
thalami, and cerebellum)
22 Turkish 8 weeks PANSS 390.48mg (mean) Not
reported
(33) EEG 10 Korean 4 weeks BPRS 20% reduction Responders:
265.6mg (mean)
Non-responders:
204.2 (mean)
Not
reported
(34) EEG 37
Canadian
Unspecified Absolute score on PANSS
(varied with machine
learning model),
quantitative clinical
assessment score 25%
reduction
50–600mg Not
reported
(35) EEG 13
Canadian
6 weeks PANSS 381.25mg (mean) Not
reported
(36) CT (prefrontal and general sulci widening) 36
American
6 months CGI- Change ≥ 2 491mg (mean) Not
reported
(37) PET (dorsolateral prefrontal, temporal,
hippocampal, thalamus, caudate and
pallidum/putamen regions)
MRI (dorsolateral prefrontal temporal, and
hippocampal regions)
25 Spanish 6 months SAPS and SANS 250–600mg Not
reported
(38) MRI (frontal—superior, caudal middle,
rostral middle, pars opercularis, pars
triangularis, pars orbitalis, lateral orbital,
medial orbital; temporal—superior
temporal, entorhinal, parahippocampal;
cingulate—caudal anterior, rostral anterior;
and occipital—lateral occipital and lingual)
11
European
1 year PANSS 220.45mg (mean) Not
reported
(39) EEG 86
American
Unspecified GAF Not reported Not
reported
(40) EEG 47
Canadian
1 year PANSS 35% reduction 347mg (mean) Not
reported
(41) SPECT (orbitofrontal, superior dorsolateral
prefrontal, anterior prefrontal, inferior
dorsolateral prefrontal, thalamic, and basal
ganglia regions)
39 Spanish 26 weeks SAPS and SANS 50%
reduction + CGI <3
551mg (mean) Not
reported
BPRS, Brief Psychiatric Rating Scale; CGI, Clinical Global Impression; CT, Computerized Tomography; EEG, Electroencephalography; GAF, Global Assessment of Functioning; MRI,
Magnetic Resonance Imaging; MRS, Magnetic Resonance Spectroscopy; PANSS, Positive and Negative Syndrome Scale; PET, Positron Emission Tomography; SAPS, Scale for the
Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms; SPECT, Single-Photon Emission Computed Tomography.
to higher levels of serotonin metabolism being associated with
better outcomes.
One study also investigated concentrations of the
noradrenaline metabolite 3-methoxy-4-hydroxyphenylglycol
(MHPG) in relation to clozapine response, and found no
association (47).
CSF Hormones
A single study investigated CSF prolactin concentrations as a
predictor of clozapine response and found no association (47).
Blood-Based Predictors of Clozapine
Response
Our search returned 11 studies which investigated biochemicals
in plasma, serum or platelets as predictors of clozapine
response (Tables 4, 5). As for CSF approaches, these
peripheral studies have also focussed on dopaminergic
and serotonergic measures. Sample sizes in these studies
ranged from 7 (42) to 50 participants (62), and all except
Kahn et al. (61) and Ertugrul et al. (26) used the BPRS to
measure symptomatic improvement. Data on plasma clozapine
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TABLE 3 | Results from neuroimaging studies.
Imaging
modality
Brain area Studies Significant
Findings
Association with good response
MRI Prefrontal Cortex (31) Y Greater right gray matter
(37) Y Greater volume (dorsolateral)
Frontal (superior, caudal middle, rostral middle, pars
opercularis, pars triangularis, pars orbitalis, lateral orbital,
medial orbital)—cortical thickness
(38) Y Thinner cortical thickness (right pars orbitalis)
Hippocampus (31) N –
(37) Y Lower volume
Temporal lobe (gray) (37) Y Greater gray matter volume
Temporal (superior temporal, entorhinal,
parahippocampal)—cortical thickness
(38) N –
Caudate (31) N –
Cingulate (caudal anterior, rostral anterior) (38) N –
Occipital (lateral occipital and lingual) (38) N –
Total intracranial volume (37) Y Lower ICV
PET Hippocampus (37) N –
Thalamus (37) N –
Pallidum/putamen (37) N –
Caudate head (37) N –
Dorsolateral prefrontal (37) Y Greater activity
Temporal (37) N –
CT General sulci widening (36) N –
Prefrontal sulci widening (36) Y Lower widening
SPECT Orbitofrontal (41) N –
Frontal (32) Y Higher perfusion
Parietal (32) N –
Temporal (32) N –
Occipital (32) N –
Caudate (32) N –
Cerebellum (32) N –
Superior dorsolateral prefrontal (41) Y Higher right perfusion
Anterior prefrontal (41) N –
Inferior dorsolateral prefrontal (41) Y Higher left perfusion
Basal ganglia (41) Y Higher perfusion
Thalamus (41) Y Higher perfusion
(32) Y Higher perfusion
EEG Unspecified (39) Y Abnormal EEG, better response
Correlation dimensions, primary lyapunov exponent, and
mutual cross prediction with electrodes at Fpl, Fp2, C3, C4,
O1, and O2
(33) No
statistical
analysis
Non-frontal-driving and occipital response patterns
associated with better response (significance testing
not done)
Machine learning approach with electrodes at Fp1, Fp2, F3,
F4, F7, F8, T3, T4, C3, C4, T5, T6, P3, P4, O1, and O2
(34) Y Discriminating variables: mutual information
between T3 & P3, T3 & O1, C3 & P3, F8 & T4;
coherence between T3 & O1, T3 & P3, C3 & O1, F3
& P3, T6 & P3, T3 & O1, T3 & T5, C3 & P3, F7 & F3;
and left to right PSD-ratio, T5/T6
Intra and inter hemispheric asymmetry with electrodes at F3,
F4, F7, F8, T3, T4, C3, C4, T5, T6, P3, P4, O1, and O2
(35) Y Greater interhemispheric central anterior temporal
theta and beta ratios, better response. Greater
intra-hemispheric frontal-anterior temporal and
anterior temporal mid temporal delta ratios, and
across majority of regions theta ratios, better
response.
Machine learning approach with electrodes at Fp1, Fp2, F7,
F3, Fz, F4, F8, T7, C3, Cz, C4, T8, P7, P3, Pz, P4, P8, O1,
O2
(40) Y Increased joint activity between midline fronto-polar
and anterior temporal right, midline fronto-polar and
parietal right, midline fronto-polar and frontal
midline, central midline and parietal right, midline
occipital-polar and parietal right
CT, Computerized Tomography; EEG, Electroencephalography; MRI, Magnetic Resonance Imaging; PET, Positron Emission Tomography; SPECT, Single-Photon Emission Computed
Tomography.
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TABLE 4 | Included blood or CSF-based studies.
Study Blood or CSF based
variables
Participant
sample
Minimum
clozapine
trial
Outcome measure Clozapine dose Plasma clozapine
(58) Platelet 5-HT2 receptor
binding (plasma)
11
American 6 weeks
BPRS Not reported Not reported
(59) HVA, MHPG, noradrenaline,
cortisol, prolactin (plasma)
14
American
6 weeks PANSS 300-900mg Not reported
(26) Serotonin (plasma, platelet,
MAO)
20 Turkish 8 weeks PANSS, CGI 382.5mg (mean) Not reported
(42) Aspartate, glutamate and
glycine (serum)
7 American 8 months
(mean)
BPRS, SANS 393mg (mean)
Not reported
(52) Adrenaline, noradrenaline,
dopamine, MHPG (plasma)
Serotonin (serum)
15 German
adolescents
6 weeks BPRS 20% reduction and
total < 34
100–600mg Responders:
114 ng/mL (mean)
Non-responders:
128 ng/mL (mean)
(60) HVA, MHPG, dopamine and
noradrenaline(plasma)
8 American 12 weeks BPRS 20% 325–500mg Not reported
(61) MCPP challenge: ACTH
Prolactin (plasma)
19
American 5 weeks
CGI 1 point reduction 584.2mg (mean) Not reported
(46) Leukocytes and neutrophils 20 Italian
8 weeks
BPRS, SAPS and SANS 365.mg (mean)
321.45 ng/mL
(62) Human leukocyte antigen
typing
50 Jewish
Israeli
12 weeks CGI score 1 or 2 >600mg Not reported
(63) MCPP challenge:
Cortisol, prolactin (plasma)
15
American
45–149
days
BPRS 440mg (mean) Not reported
(47) HVA, 5-HIAA, MHPG and
noradrenaline (CSF)
HVA, noradrenaline (plasma)
Prolactin (serum)
21
American
14 weeks BPRS 20% reduction
AND BPRS score less
than 36 or
Bunney-Hamburg Global
Psychosis Rating of less
than 6 (mild psychosis)
225–600mg 430 ng/mL (mean)
(64) HVA, 5-HIAA (CSF) 10
American
42 weeks BPRS 450–650mg Not reported
(65) HVA (plasma) 18
American
6 months BPRS 20% reduction Responders:
507.1mg (mean)
Non-responders:
468.2mg (mean)
Not reported
(66) Glycine, serine (plasma) 44
American
6 weeks SANS, BPRS 353.7mg (mean) Not reported
(48) HVA, 5-HIAA (CSF)
HVA (plasma)
19
American
6 weeks BPRS 20% reduction, CGI
≥ 3
404mg (mean) 253 ng (mean at 3
weeks)
(67) Prolactin, growth hormone
(plasma)
7 White
American
3 African
American
12 weeks BPRS 591.7mg (mean) Not reported
5-HIAA, 5-Hydroxyindoleacetic Acid; ACTH, Adrenocorticotropic Hormone; BPRS, Brief Psychiatric Rating Scale; CGI, Clinical Global Impression; CSF, Cerebrospinal Fluid; GAF, Global
Assessment of Functioning; HVA, Homovanillic Acid; MAO, Monoamine Oxidase; MCPP, Meta-Chlorophenylpiperazine; MHPG, 3-Methoxy-4-hydroxyphenylglycol; PANSS, Positive and
Negative Syndrome Scale; SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms.
concentrations were unavailable in all but three of the studies
(47, 48, 52).
Blood Monoamines
Several studies have investigated peripheral dopaminergic
variables as predictors of clozapine response, with overall
negative or inconclusive findings. Two studies investigated
plasma dopamine concentrations, both with negative findings
(52, 60). The five studies which investigated concentrations
of the dopamine metabolite HVA in plasma have reported
mixed findings. Pickar et al. (47) initially reported that
lower baseline plasma HVA concentrations were associated
with greater reductions in symptoms, but three later studies
reported that higher baseline plasma HVA concentrations
were associated with greater symptom reduction (59, 60, 65),
although one study found this only for negative symptoms
(59) and one study found this only as a correlation with
positive symptoms within the clozapine responder group
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TABLE 5 | Results from CSF and blood-based studies.
Studies Significant
Findings
Association with
good response
ACTH (61) Y Greater increase
after MCPP
challenge
CSF 5-HIAA (47) N –
(64) N –
(48) N –
HVA (47) N –
(64) N –
(48) N –
HVA:5-HIAA (47) Y Low ratio
(64) Y Low ratio
(48) Y Low ratio
MHPG (47) N –
Noradrenaline (47) N –
HLA typing (62) N –
Leukocytes (46) N –
Neutrophils (46) N –
Plasma Adrenaline (52) Y Low concentration
(60) Y Low concentration
Cortisol (59) N –
(63) Y Greater increase
after MCPP
challenge
Dopamine (52) N –
(60) N –
Glycine (66) Y Higher
concentration
Growth
hormone
(67) Y Greater increase
after apomorphine
challenge
HVA (59) Y Lower
concentration (neg
symptoms)
(60) Y Higher
concentration
(47) Y Lower
concentration (in
responders)
(65) Y –
(48) N –
MHPG (59) N –
(52) N –
(60) N –
Noradrenaline (59) N –
(52) N –
(60) N –
(47) N –
Prolactin (59) N –
(61) N –
(63) N –
(67) Y Greater decrease
after apomorphine
challenge
(Continued)
TABLE 5 | Continued
Studies Significant
Findings
Association with
good response
Serine (66) N –
Serotonin (26) N –
Platelets MAO (26) Y Higher
concentration
Serotonin (26) Y Lower
concentration
(58) Y Lower receptor
availability
Serum Aspartate (42) N –
Glutamate (42) N –
Glycine (42) Y Lower
concentration
Prolactin (47) N –
Serotonin (52) N –
5-HIAA, 5-Hydroxyindoleacetic Acid; ACTH, Adrenocorticotropic Hormone; CSF,
Cerebrospinal Fluid; HVA, Homovanillic Acid; MAO, Monoamine Oxidase; MCPP, Meta-
Chlorophenylpiperazine; MHPG, 3-Methoxy-4-hydroxyphenylglycol.
(65). A further study found no association between plasma
HVA and clozapine response (48). One study investigated
concentrations of platelet monoamine oxidase B (MAO-B) which
metabolizes dopamine (68), and found a positive association with
symptom improvements following clozapine (26). Finally, as a
dopaminergic pharmacological challenge, apomorphine-induced
prolactin suppression and growth hormone secretion predicted
better clozapine response in a preliminary study (67).
In terms of peripheral serotonergic studies, Ertugrul et al.
(26) found no association with plasma serotonin concentrations
and clozapine response as did an earlier study of serum
serotonin concentrations in children and adolescents (52).
However, Ertugrul et al. (26) also reported a negative correlation
between platelet serotonin concentrations, (reflecting uptake of
plasma serotonin through platelet serotonin transporters) and
improvement in positive symptoms following clozapine. Arora
and Meltzer (58) measured platelet 5HT2 receptor binding in
platelet-rich plasma and reported that a lower number of 5HT2
binding sites before clozapine initiation was associated with
poorer treatment outcomes.
Pharmacological serotonin challenge using the non-selective
5-HT receptor agonist m-chlorophenylpiperazine (mCPP) has
also been employed to investigate clozapine response (61,
63). mCPP-induced adrenocorticotropic hormone (ACTH)
release (61) and plasma cortisol (63) were directly associated
with improvement in symptoms. In contrast, there was no
association between MCPP-induced prolactin increase and
clozapine response in either study (61, 63). The finding of
increased MCPP-responses would suggest that elevated 5-HT
system function is associated with better clinical responses to
clozapine.
Finally, four studies investigated adrenaline, noradrenaline
or MHPG concentrations. Two studies reported that low
plasma adrenaline concentrations associate with better clozapine
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TABLE 6 | Included cardiac studies.
Study Cardiac
variable
Participant
sample
Minimum
clozapine trial
Outcome
measure
Clozapine dose Plasma
clozapine
(70) ECG:
heart-rate
variability
40 Korean 8 weeks PANSS Responders:
250mg (mean)
Non-responders:
266mg (mean)
Not reported
ECG, Electrocardiogram; PANSS, Positive and Negative Syndrome Scale.
TABLE 7 | Results from cardiac studies.
Studies Significant
findings
Association with
good response
ECG Heart rate variability 55 N –
ECG, Electrocardiogram.
response (52, 60). In contrast, studies have found no association
between plasma noradrenaline concentrations (47, 52, 59, 60), or
plasma MHPG and clozapine response (52, 59, 60).
Blood Glutamatergic Amino Acids
The glutamatergic amino acids glycine and serine act
as endogenous co-agonists at the N-methyl-D-aspartate
(NMDA) glutamate receptor complex, which is thought to be
hypofunctional in schizophrenia and therefore increasing glycine
or serine levels may have therapeutic potential (69). Two studies
(42, 66) investigated glycine and serine concentrations in relation
to clozapine response, from serum and plasma respectively, and
have produced conflicting evidence. In a sample of 7 patients,
Evins et al. (42) found that lower serum glycine concentrations
predicted a better response to clozapine, whereas in the larger
and longer-term study of Sumioyshi et al. (66) higher plasma
glycine concentrations and higher plasma glycine/serine ratios
predicted greater negative symptom improvements, whereas
no associations were found between serine concentrations
and clozapine response. Evins et al. (42) also measured
glutamate and aspartate concentrations and report no significant
associations.
Blood Hormones
One study investigated serum prolactin levels (47) and another
investigated plasma prolactin and cortisol levels (59). Neither
of these studies reported significant associations with clozapine
response.
Blood Immunological Variables
Two studies have looked at immological variables as predictors
of clozapine response. Mauri et al. (46) measured neutrophil
and leukocyte numbers before 8 weeks of clozapine treatment
in 20 patients. They do not report significance testing but
provide summary statistics; independent t-tests using this data
indicates no association with response to clozapine. Meged et al.
(62) investigated human leukocyte antigen (HLA) type in 50
Israeli patients but found no association between HLA type and
response to clozapine after 12 weeks.
Cardiac Predictors of Clozapine Response
One study investigated heart rate variability in 40 participants
with treatment-resistant schizophrenia using ECG (70) but did
not find any pre-clozapine differences in heart rate variability
associated with changes in BPRS after 8 weeks of clozapine
treatment (Tables 6, 7).
Genetic Predictors of Clozapine Response
We identified a total of 70 studies investigating associations
between genetic variants and clozapine response (Tables 8–11).
In the first study of its kind, Frank et al. (83) recently reported
that higher genetic risk of schizophrenia, calculated as the
schizophrenia polygenic risk score (131), was associated with
a poorer degree of response to clozapine1. Butcher et al. (82)
recently reported that individuals with a large chromosomal
deletion (22q11.2) respond as well to clozapine as patients with
schizophrenia who do not have this deletion.
Of the other genetic studies, seven reported significant
associations between genetic haplotypes of DRD1, DRD2, DRD3,
FKBP5, GFRA2, HTR3A, and NTRK2 (43, 88–91, 119) (see
Table 10) and clozapine response, but none of these have been
replicated. Two unreplicated studies also reported significant
associations between gene-gene interactions of DRD1 and
DRD2, DRD2 and DRD3, DRD1 and GRIN2A, and GFRA1,
GFRA2, and GFRA3 (92, 119) and clozapine response (see
Table 11).
Two studies reported the predictive validity of multivariate
genetic models. One study investigated a logistic regression
analysis with a combination of six polymorphisms (T102C
and His452Tyr of HTR2A gene, G-330T/ C-244T repeat and
Cys23Ser of HTR2C gene, HTTLPR of SLC6A4 gene, G-1018A
of HRH1) which was able to predict clozapine response with
the retrospective positive predictive value of 76.7%, negative
predictive value of 82%, a sensitivity of 95% and specificity of
38% (76). A more recent study used an artificial neural network
analysis to combine five genetic polymorphisms (T102C of the
HTR2A gene, Arg347Cys of the ADRA1A gene, −1291 C>G of
the ADRA2A gene, Trp64Arg of the ADRB3 gene, and 825 C>T
of the GNB3 gene), which were insignificant individually, with
clinical predictor variables (gender, age, height, baseline body
1This was clarified directly with the corresponding author for this paper due to
discrepancies between the text and figure in the paper.
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TABLE 8 | Included genetic studies.
Study Genetic
variant
Participant
sample
Minimum
clozapine trial
Outcome
measure
Clozapine dose Plasma clozapine
(71) HTR2A 149 White
European
3 months GAS 20-point improvement 125–600mg Not reported
(72) CYP2D6 123 White
European
2 months GAS 20-point improvement 125–600mg Not reported
(73) HTR2A 153 White
European
Not reported GAS 20-point improvement 125–600mg Not reported
(55) DRD2 151 White British
146 Han Chinese
Not reported GAS 20-point improvement
or personal interview
Not reported Not reported
(74) HTR2A Sample 1–160
Sample 2–114
White British
3 months GAS 20-point improvement 125–600mg Not reported
(75) 5-HTT 268 White British 3 months GAS 20-point improvement Not reported Not reported
(76) ADRA2A
ADRA1A
DRD3
HTR2A
HTR2C
HTR3A
HTRA5
5-HTT
HRH1
HRH2
200 White British Not reported GAS “retrospective
evaluation”
Not reported Not reported
(77) DRD3 92 Turkish 16 weeks BPRS, SAPS and SANS
30% reduction
308.2mg (mean) Not reported
(78) HTR5A 269 White British 3 months GAS “retrospective
evaluation”
Not reported Not reported
(79) ADRA1A
ADRA2A
289 White British 3 months GAS 20-point improvement Not reported Not reported
(80) COMT
5- HTR1A
107 Italian 12 weeks PANSS 30% reduction 229mg (mean) Not reported
(81) ITIH3 143 American 6 months BPRS 25% reduction Not reported Not reported
(82) 22q11.2
deletion
40 Canadian Not reported CGI 325mg (mean) Not reported
(53) CYP2D6 34 German 10 weeks BPRS 20% reduction Responders:
320mg (mean)
Non-responders:
313mg (mean)
Responders:
211ng/mL (mean)
Non-responders:
269 ng /mL (mean)
(83) Polygenic risk
score
123 German Not reported 4 level ordinal
physician-rated scale of
improvement
Not reported Not reported
(84) HTR3A
HTR3B
266 White British 3 months GAS 20-point improvement Not reported Not reported
(85) GRIN2B 100 Han Chinese 8 weeks BPRS 20% reduction Not reported Not reported
(86) BDNF 93 Han Chinese 8 weeks BPRS 20% reduction Not reported Not reported
(87) APOE 95 Chinese 8 weeks BPRS 275.5mg (mean) Not reported
(88) DRD2 183 White
American
49 African
Americans
6 months BPRS 20% reduction Not reported Not reported
(89) DRD2 97 White
American
35 African
Americans
6 months BPRS, BPOS, BNEG Not reported Not reported
(Continued)
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TABLE 8 | Continued
Study Genetic
variant
Participant
sample
Minimum
clozapine trial
Outcome
measure
Clozapine dose Plasma clozapine
(90) DRD1 183 White
American
49 African
Americans
6 months BPRS 20% reduction Not reported Not reported
(91) DRD3 183 White
American
49 African
American
6 months BPRS 20% reduction Not reported Not reported
(92) GRIN1
GRIN2A
GRIN2B
DRD1
DRD2
DRD3
183 White
American
49 African
American
6 months BPRS 20% reduction Not reported Not reported
(93) DRD4
DRD5
183 White
American
6 months BPRS 20% reduction Not reported Not reported
(94) DRD2 151 White
American 42
African American
15 others
6 months BPRS 20% reduction Not reported Not reported
(95) NTSR1 196 White British 3 months GAS 20 point reduction Not reported Not reported
(96) 5-HTT 188 White German 5 weeks CGI, PANSS 50–800mg Not reported
(97) GNB3 121 European 3 months BPRS 30% reduction 540.91mg (mean) Not reported
(98) 5-HTT 116 European 3 months BPRS 30% reduction 539.22mg (mean) Not reported
(45) DRD4 74 Israeli (including
Jews of European,
North African and
Asian origin)
16 months Retrospective interview 365mg (mean) Not reported
(54) ABCB1
ADRA1A
ADRA2A
ANKK1
CHRM1
CYP1A2
CYP2C19
CYP2D6
CYP3A4
CYP3A43
CYP3A5
CYP3A7
DRD1
DRD2
DRD3
DRD4
DTNBP1
GNB3
GSK3B
HRH1
HTR2A
HTR3A
HTR6
SLC6A4
UGT1A3
UGT1A4
96 Korean 6 months CGI score Responders:
353.1mg (mean)
Non-responders:
312.2mg (mean)
Responders:
662.4 ng/mL (mean)
Non-responders:
627.2 ng/mL (mean)
(99) NRXN1 163 European-
American
6 months BPRS 20% reduction Not reported Not reported
(Continued)
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TABLE 8 | Continued
Study Genetic
variant
Participant
sample
Minimum
clozapine trial
Outcome
measure
Clozapine dose Plasma clozapine
(100) HTR2A 97 Chinese 8 weeks BPRS Not reported Not reported
(101) HTR2A
ADRA1A
ADRA2A
ADRB3
GNB3
93 Taiwanese 3 months CGI score of 1 or 2 388.2mg (mean) Not reported
(102) HTR2A 70 American 10 weeks BPRS 20% reduction 405mg (mean) Not reported
(103) HTR2C 66 American 10 weeks BPRS 20% reduction 409mg (mean) Not reported
(104) DRD3 68 American 4 and 10 weeks BPRS 20% reduction 4 week group:
497mg (mean)
10 week group:
408mg (mean)
Not reported
(105) HRH1
HRH2
158 White British 3 months GAS 20-point improvement Not reported Not reported
(106) HTR2A
HTR2C
144 White
American
40 African
American
1 Asian American
6 months BPRS 20% reduction
OR
15–20% reduction in BPRS
score and a reduction of 1+
CGI category
Not reported Not reported
(107) HTR6 144 White
American
40 African
American
1 Asian American
6 months BPRS 20% reduction
OR
15–20% reduction in BPRS
score and a reduction of 1+
CGI category
Not reported Not reported
(43) FKBP5
NR3C1
BDNF
NTRK2
591 White British 3 months GAS 20-point improvement Not reported Not reported
(30) GNB3 77 White
American
57 African
American
11 Other American
11 weeks BPRS Not reported Not reported
(44) HTR2A 146 German 4 weeks GAS 20 point improvement 100 mg+ Not reported
(108) BDNF 120 European 8 weeks PANSS 50% reduction 100–500mg Not reported
(109) DRD1
DRD3
HTR2A
HTR2C
13 White
American
2 African American
5 weeks BPRS 460mg (mean) Not reported
(49) HTR3A 101 South Indian 12 weeks BPRS total scores ≤35 340.84mg (mean) 550.53 ng/mL (mean)
(110) DRD4 29 American 20 weeks BPRS 20% reduction AND
BPRS score less than 36 or
Bunney-Hamburg Global
Psychosis Rating of less
than 6 (mild psychosis)
”moderate” dose
for first 5 weeks;
”optimized” dose
for 15 weeks
Not reported
(111) DRD4 148 German 10 weeks GAS 20-point improvement
AND
BPRS 20% reduction
AND
BPRS score less than 36 or
Bunney-Hamburg Global
Psychosis rating less than 6
451.1mg (mean) Not reported
(112) HTR2C 231 German 4 weeks SADS-L Male-−423.4mg
(mean)
Female-
−407.9mg
(mean)
Not reported
(Continued)
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TABLE 8 | Continued
Study Genetic
variant
Participant
sample
Minimum
clozapine trial
Outcome
measure
Clozapine dose Plasma clozapine
(113) DRD3 32 Pakistani 6 months BPRS 50% reduction <600mg Not reported
(114) DRD4 147 White
European
42 Taiwan Chinese
3 months GAS 20-point improvement 150–900mg Not reported
(115) DRD3 183 White
European
3 months GAS 20-point improvement 150–900mg Not reported
(116) HTR2A
HTR2C
162 White
European
3 months GAS 20-point improvement 125–600mg Not reported
(117) GPX1
MNSOD
171 White
American
45 African
American
6 months BPRS 20% reduction Not reported Not reported
(118) HTR3A
HTR3B
114 White
American
26 African
American
6 months BPRS 20% reduction Not reported Not reported
(119) GFRA1
GFRA2
GFRA3
GFRA4
114 White
American
26 African
American
6 months BPRS 20% reduction Not reported Not reported
(120) OXT
OXTR
114 White
American
26 African
American
6 months BPRS 20% reduction Not reported Not reported
(121) GSK3 114 White
American
26 African
American
6 months BPRS 20% reduction Not reported Not reported
(122) NRXN1 114 White
American
26 African
American
6 months BPRS 20% reduction Not reported Not reported
(123) GRIN2B 175 Europeans 6 months BPRS 20% reduction 453mg (mean) Not reported
(124) 5-HTT 90 Han Chinese 8 weeks BPRS 272mg (mean) Not reported
(125) ADRA2A 97 Han Chinese 8 weeks BPRS 20% reduction 276mg (mean) Not reported
(126) TNF 99 Han Chinese 4 months BPRS 275.5mg (mean) Not reported
(91) TNF 55 Chinese 14 months CGI score of 1 or 2 400mg (mean) Not reported
(50) SLC6A3 160 Han Chinese 8 weeks BPRS 40% reduction 300–600mg 434 ng/mL (mean)
(127) ABCB1
ACSM1
AGBL1
AKT1
ANK3
BDNF
COMT
CYP1A2
CYP2C19
CYP2C9
CYP2D6
CYP3A4
DRD2
DRD3
GRM3
HTR2C
NOTCH4
240 Han Chinese 2 months PANSS 50% reduction 122mg (mean) Not reported
(Continued)
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TABLE 8 | Continued
Study Genetic
variant
Participant
sample
Minimum
clozapine trial
Outcome
measure
Clozapine dose Plasma clozapine
PLAA
RELN
SHISA9
SLC1A1
SLC6A2
SLC6A3
TCF4
TNIK
(128) HTR6 99 Chinese 8 weeks BPRS 20% reduction Not reported Not reported
(129) TNF-α 71 White
American
25 African
American
6 weeks, 3
months, 6 months
BPRS Not reported Not reported
(51) DRD4 81 Han Chinese 2 months PANSS 50% reduction 200–450mg 712.1 ng/mL (mean)
(130) DTNBP1 58 European
American
27 African
American
3 months PANSS 20% reduction 203mg (mean) Not reported
BPRS, Brief Psychiatric Rating Scale; CGI, Clinical Global Impression; GAF, Global Assessment of Functioning; PANSS, Positive and Negative Syndrome Scale; SADS-L, Schedule for
Affective Disorders and Schizophrenia; SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms.
weight, baseline body mass index) (101). This approach was able
to retrospectively identify all clozapine responders and 76.5%
clozapine non-responders.
However, our search mainly returned studies that have
employed candidate gene approaches to investigation of
clozapine response. Overall, these studies have investigated
associations with clozapine response for a total of 379
different gene variants, 362 of which relate to single nucleotide
polymorphisms (SNPs). For these studies, we limit comment
to significant findings with at least one replication. Of the 379
different gene variants investigated, significant findings have been
reported for 40 variants, 8 of which have been replicated. 28
variants have replicated null results with no significant findings,
including the rs6275 and rs6277 polymorphisms of DRD2 (54,
88, 127) and the val66met polymorphism in BDNF (43, 86,
108, 127). The details for all genetic studies, including those
with non-significant or non-replicated findings, are provided in
Table 9.
Dopaminergic Genes
The DRD3 gene, encoding the D3 dopamine receptor, has been
investigated in nine studies, all of which have investigated the
Ser9Gly polymorphism of rs6280. While two initial studies
independently reported that the Gly allele was associated with
a good response to clozapine (113, 115), all seven subsequent
studies found non-significant results (54, 76, 77, 91, 104, 109,
127), including the two studies with the largest sample size
(76, 91).
Serotonergic Genes
The HTR2A gene, encoding the 5-HT2A receptor at which
clozapine has high affinity, has been investigated in 12 studies.
The His allele of His452Tyr has been associated with good
response to clozapine in four studies conducted by two
research groups (73, 74, 76, 106), although two studies did
not detect this association (44, 102). Within the same gene,
the T allele of the T102C polymorphism has been associated
with good response to clozapine in three studies by the
same research group (71, 76, 116), although seven studies
by other groups have failed to replicate these findings (44,
54, 100–102, 106, 109). The G-1438A SNP also significantly
predicted clozapine response in two studies by the same
group (74, 76) but these results were not replicated in a
second sample analyzed by the same research group (74) or in
separate samples from two independent research groups (54,
106).
The HTR3A gene has been investigated in five studies (49, 54,
76, 84, 118); the only SNP which has been reported more than
once, across all five studies, is rs1062613, with one study finding
that good response to clozapine was associated with the T allele
(49), another finding that good clozapine response was associated
with the C allele (118) and the other three studies reporting no
association.
The 5HTT (or SLC6A4) gene, encoding the serotonin
transporter, has been investigated in six studies by five
independent groups (54, 75, 76, 96, 98, 124), with the only
independently replicated finding for an association of the
HTTLPR polymorphism at rs25531 with clozapine response;
Kohlrausch et al. (98) found an association between good
response and the long allele, but Arranz et al. (76) do not report
the direction of effect.
Other Gene Variants
An association between the C allele of the C825T polymorphism
in the gene encoding G-protein subunit-beta 3 (GNB3) and a
good response to clozapine has been reported in two studies
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TABLE 9 | Results for individual genetic variants.
Polymorphism Study Significant
findings
(N or Y)
Association with
good response to
clozapine (unless
stated otherwise)
22q11.2 deletion (82) N –
ABCB1 rs10248420 (54) Y G allele
rs10276036 (54) N –
rs10280101 (54) N –
rs1045642 (54) N –
(127) N –
rs1128503 (54) N –
(127) N –
rs11983225 (54) N –
rs12720067 (54) N –
rs1978095 (127) N –
rs2032582 (54) N –
(127) Y C allele
rs2032583 (54) N –
rs2235015 (54) N –
rs3213619 (54) N –
rs35023033 (54) N –
rs35730308 (54) N –
rs35810889 (54) N –
rs3747802 (54) Y A allele
rs4148739 (54) N –
rs4148740 (54) N –
rs72552784 (54) N –
rs7787082 (54) N –
rs9282564 (54) N –
ACSM1 rs433598 (127) N –
ADRA1A Arg492Cys (76) N –
(79) N –
(101) N –
rs1048101 (54) N –
ADRA2 −1291-C/G (76) N –
(79) N –
(101) N –
(125) N –
−261-G/A (76) N –
(79) N –
rs1800038 (54) N –
rs1800763 (54) N –
rs521674 (54) N –
rs553668 (54) N –
rs602618 (54) N –
ADRB3 Trp64Arg (101) N –
AGBL1 rs16977195 (127) N –
AKT1 rs2494732 (127) N –
rs2494738 (127) N –
rs3001371 (127) Y T allele
rs3803300 (127) N –
ANKK1 rs10891545 (54) N –
rs11604671 (54) N –
rs17115439 (54) N –
rs1800497 (54) N –
rs4938013 (54) N –
(Continued)
TABLE 9 | Continued
Polymorphism Study Significant
findings
(N or Y)
Association with
good response to
clozapine (unless
stated otherwise)
ANK3 rs10761482 (127) N –
APOE E4 positive or
negative
(87) N –
BDNF rs6265 (val66met) (86) N –
(43) N –
(108) N –
(127) N –
rs11030076 (43) N –
rs11030096 (43) N –
rs1552736 (43) N –
CHRM1 rs2067477 (54) N –
COMT rs1544325 (127) N –
rs165599 (127) N –
rs174696 (127) N –
rs174697 (127) N –
rs174699 (127) N T allele
rs4646312 (127) N –
rs4646316 (127) Y –
rs4680 (Val158Met) (80) N –
(127) N –
rs4818 (127) N –
rs5993883 (127) N –
rs6269 (127) N –
rs737865 (127) N –
CYP1A2 rs762551 (54) N –
(127) N –
rs12720461 (54) N –
rs2069521 (54) N –
rs2069522 (54) N –
rs2069526 (54) N –
rs2470890 (54) N –
rs55889066 (54) N –
rs72547516 (54) N –
CYP2C19 rs11188072 (54) N –
rs11568732 (54) N –
rs12248560 (54) N –
rs17884712 (54) N –
rs2104161 (127) N –
rs41291556 (54) N –
rs4244285 (54) N –
(127) N –
rs4986893 (54) N –
(127) N –
rs4986894 (54) N –
rs56337013 (54) N –
(127) N –
CYP2C9 rs1057910 (127) N –
rs1934969 (127) N –
CYP2D6 Unspecified (72) N –
(53) N –
rs1065852 (54) N –
(127) N –
(Continued)
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TABLE 9 | Continued
Polymorphism Study Significant
findings
(N or Y)
Association with
good response to
clozapine (unless
stated otherwise)
rs1135840 (54) N –
(127) N –
rs16947 (54) N –
(127) N –
rs28371720 (54) N –
rs28371725 (54) N –
rs3892097 (54) N –
(127) N –
rs4986774 (54) N –
rs5030655 (54) N –
rs59421388 (54) N –
rs61736512 (54) N –
CYP3A4 rs2242480 (127) Y C allele
rs2246709 (54) N –
rs2740574 (54) N –
rs28371759 (54) N –
(127) N –
rs4986907 (54) N –
rs4986909 (54) N –
rs4986910 (54) N –
rs4986913 (54) N –
rs4987161 (54) N –
CYP3A43 rs17342647 (54) N –
rs61469810 (54) N –
rs680055 (54) N –
CYP3A5 rs10264272 (54) N –
rs776746 (54) N –
CYP3A7 rs2257401 (54) N –
DTNBP1 rs1018381 (130) N –
rs2619538 (54) N –
rs2619539 (54) N –
(130) N –
rs3213207 (54) N –
rs742105 (54) N –
(130) Y T allele
rs742106 (130) N –
rs760761 (130) N –
rs909706 (54) N –
(130) N –
DRD1 rs265976 (90) Ya AC genotype—non
responders
rs265981 (90) N –
rs4532 (−48 AG) (90) N –
(109) Y “2/2 genotype”
rs5328 (54) N –
rs686 (90) N –
DRD2 −141 Ins/Del C (55) N –
(88)* N –
rs1076560 (54) N –
rs1076562 (127) N –
rs1079598 (Taq1B
C/T)
(88)* Ya T allele
(Continued)
TABLE 9 | Continued
Polymorphism Study Significant
findings
(N or Y)
Association with
good response to
clozapine (unless
stated otherwise)
rs1079727 (127) N –
rs1125394 A/G (88)* Ya A allele
(127) N –
rs12364283 (54) N –
rs1799978 (88)* N –
(54) N –
(127) N –
rs1800497 (88)* Ya C allele
(127) N –
rs1800498 (Taq1D
C/T)
(88)* N –
rs1801028
(Ser311Cys)
(54) N –
rs2075652 (127) N –
rs2242591 A/G (88)* N –
rs2242592 C/T (88)* N –
rs2242593 A/G (88)* N –
rs2283265 (54) N –
(127) N –
rs2514218 A/G (94) Yw A allele
rs4648317 C/T (88)* N –
rs4648318 (127) N –
rs6275 (NcoI C/T) (88)* N –
(54) N –
(104) N –
(115) Y Gly 9 allele
(127) N –
(77) N –
rs6277 (C957T ) (88)* N –
(91) N –
(54) N –
(127) N –
rs7103679 (127) N –
rs7131056 (127) N –
DRD3 rs1394016 (91) N –
rs167770 (91) N –
rs167771 (54) N –
(127) Y G allele
rs2087017 (91) N –
rs2134655 (91) Yw A allele
rs2399504 (91) N –
rs324036 (127) N –
rs6280 (Ser-9-Gly) (76) N –
(77) N –
(91) N –
(54) N –
(104) N –
(113) Y Gly 9 allele
(115) Y Gly 9 allele
(109) N –
(127) N –
rs6762200 (91) N –
rs7611535 (91) N –
(Continued)
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TABLE 9 | Continued
Polymorphism Study Significant
findings
(N or Y)
Association with
good response to
clozapine (unless
stated otherwise)
rs905568 (91) N –
rs963468 (127) N –
DRD4 12 bp repeat (45) N –
(111) N –
13 bp repeat (111) N –
48 bp repeat (93) N –
(45) N –
(110) N –
(111) N –
(114) N –
(51) Y 5 allele—non-
responders
120 bp repeat (93) N –
G(n) repeat (93) N –
Gly11Arg (111) N –
rs11246226 (93) N –
(54) N –
rs3758653 (93) N –
(54) N –
rs916457 (54) N –
rs936465 (93) N –
DRD5 CA/CT/GT
dinucleotide
microsatellite
repeat
(93) N –
rs10001006 (93) N –
rs10033951 (93) N –
rs1967551 (93) N –
rs6283 (93) N –
FKBP5 rs1360780 (43) Y C allele
rs17542466 (43) N –
rs2766533 (43) N –
rs3777747 (43) N –
GFRA1 rs1078080 (118) N –
rs10749189 (118) N –
rs10787627 (118) N –
rs10885877 (118) N –
rs10885888 (118) N –
rs11197557 (118) N –
rs11197567 (118) N –
rs11197612 (118) N –
rs11598215 (118) N –
rs11812459 (118) N –
rs12413585 (118) N –
rs12775655 (118) N –
rs12776813 (118) N –
rs17094340 (118) N –
rs2694783 (118) N –
rs2694801 (118) N –
rs3781514 (118) N –
rs3781539 (118) N –
rs3824840 (118) N –
rs4751956 (118) N –
rs7085306 (118) N –
rs730357 (118) N –
rs7903297 (118) N –
(Continued)
TABLE 9 | Continued
Polymorphism Study Significant
findings
(N or Y)
Association with
good response to
clozapine (unless
stated otherwise)
rs7920934 (118) N –
rs9787429 (118) N –
GFRA2 rs15881 (118) N –
rs10088105 (118) N –
rs10283397 (118) N –
rs1128397 (118) N –
rs11993990 (118) N –
rs13250096 (118) N –
rs4078157 (118) N –
rs4237073 (118) N –
rs4567027 (118) N –
rs4567028 (118) N –
rs4739217 (118) N –
rs4739285 (118) N –
rs4739286 (118) N –
rs6587002 (118) N –
rs6988470 (118) N –
rs7014143 (118) N –
rs7813735 (118) N –
GFRA3 rs10036665 (118) N –
rs10952 (118) N –
rs11242417 (118) N –
rs7726580 (118) N –
GFRA4 rs6084432 (118) N –
rs633924 (118) N –
GNB3 rs1129649 (54) N –
rs3759348 (54) N –
rs5439 (54) N –
rs5440 (54) N –
rs5441 (54) N –
rs5442 (54) N –
rs5443 (C825T) (97) Y C allele
(54) N –
(101) N –
(30) Yw C/C genotype
rs5446 (54) N –
GPX1 rs1050450
(Pro200Leu)
(117) N –
GRIN1 rs11146020
(G1001C)
(92) N –
GRIN2A GT dinucloedtide
repeat
microsatellite
polymorphism in
promoter region
(92) N –
GRIN2B rs10193895
(G-200T)
(92) N –
rs1072388 (123) N –
rs12826365 (123) N –
rs1806191 (123) N –
rs1806201
(C2664T )
(85) N –
(123) N –
rs2284411 (123) N –
(Continued)
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TABLE 9 | Continued
Polymorphism Study Significant
findings
(N or Y)
Association with
good response to
clozapine (unless
stated otherwise)
rs3764030 (123) N –
rs890 (123) N –
GRM3 rs274622 (127) N –
rs724226 (127) N –
GSK3B rs11919783 (121) N –
rs11923196 (121) N –
rs13319151 (121) N –
rs13321783 (54) N –
rs2319398 (54) N –
rs334558 (54) N –
rs3755557 (121) N –
rs3755557 (121) N –
rs4072520 (121) N –
rs4491944 (121) N –
rs4688043 (121) N –
rs6438552 (121) N –
rs6772172 (121) N –
rs6779828 (121) N –
rs6805251 (121) N –
rs6808874 (54) N –
rs7624540 (121) N –
rs9846422 (121) N –
rs9846422 (121) N –
rs9878473 (121) N –
HRH1 −17-C/T (105) N –
Leu449Ser (76) N –
−974-C/A (105) N –
−1023-A/G (105) N –
−1536-G/C (105) N –
rs12490160 (54) N –
rs13064530 (54) N –
rs6778270 (54) N –
HRH2 −1010- G/A (76) N –
−294-A/G (105) N –
−592-A/G (105) N –
−1018-G/A (105) N –
−1077-G/A (105) N –
HTR1A C->T 47 (107) N –
rs6295 (−1019
C/G)
(80) N –
HTR2A his452tyr (73) Y His allele
(74) Y His allele
(76) Y His allele
(102) N –
(106) Y His allele
(44) N –
Thr25Asp (76) N –
(44) N –
516-C/T (76) N –
rs6311 (G-1438A) (106) N –
(74)
sample 1
Y GG genotype—
non-responders
(74) sample 2 N –
(Continued)
TABLE 9 | Continued
Polymorphism Study Significant
findings
(N or Y)
Association with
good response to
clozapine (unless
stated otherwise)
(76) Y Not reported
(54) N –
rs6313 (T102C) (71) Y T102 allele
(76) Y T102 allele
(54) N –
(100) N –
(101) N –
(102) N –
(106) N –
(44) N –
(109) N –
(116) Y T102 allele
rs7997012 (54) N –
rs9316233 (54) N –
HTR2C Cys23ser (116) Y Ser allele
(106) N –
(76) N –
(109) N –
(112) N –
(103) N –
−330–GT/ 244–CT
repeat
(76) Y Not reported
rs1023574 (127) N –
rs1414334 (127) N –
rs2192371 (127) N –
rs3813929 (127) Y C allele
rs498177 (127) Y G allele
rs518147 (127) N –
rs5988072 (127) N –
rs9698290 (127) N –
HTR3A rs1062613
(178-C/T)
(76) N –
(84) N –
(54) N –
(49) Y T allele
(118) Y C allele
rs1150226 (118) N –
rs1176713 (54) N –
(118) N –
rs2276302
(1596-A/G)
(76) N –
(84) N –
(49) Y G allele
(118) N –
HTR3B a CA repeat
polymorphism
(84) N –
rs1176744 (118) N –
rs2276307 (118) N –
rs3758987 (118) N –
rs3782025 (118) N –
HTR5 −19G/C (76) N –
(78) N –
12A/T (76) N –
(78) N –
(Continued)
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TABLE 9 | Continued
Polymorphism Study Significant
findings
(N or Y)
Association with
good response to
clozapine (unless
stated otherwise)
HTR6 T->C 267 (107) N –
(128) Y TT genotype
rs1805054 (54) N –
HTR7 pro279leu (107) N –
5HTT VNTR (76) N –
(75) N –
VNTR Stin2 (96) N –
Ins/Del 44 bp (96) N –
(98) N –
484 vs. 528 bp (124) N –
rs6352 (54) N –
rs2020934 (54) N –
HTTLPR repeat (76) Y Not reported
(98) Y Long allele
(75) N –
ITIH4 rs2535629 (81) Y A allelea
MNSOD rs4880 (Ala16Val) (117) N –
NOTCH4 rs3131296 (127) N –
NR3C1 rs1837262 (43) N –
rs2963156 (43) N –
rs4634384 (43) N –
rs4912910 (43) N –
NRXN1 rs1045881 C/T (99) Y C allele
rs10490162 (122) N –
rs12467557 (122) N –
rs1400882 (122) N –
rs17041112 (122) N –
NTRK2 rs10465180 (43) Y T allele
rs1619120 (43) N –
rs1778929 (43) Y C allele
rs4388524 (43) N –
NTRS1 3020-T/C (95) N –
VNTR in 3′-flanking
region
(95) N –
OXT rs2740204 (120) Y G allele
rs2740210 (120) N –
rs2770378 (120) N –
rs3761248 (120) N –
rs4813625 (120) N –
rs877172 (120) N –
OXTR rs1042778 (120) N –
rs11131149 (120) N –
rs11706648 (120) N –
rs2268492 (120) N –
rs2268496 (120) N –
rs237884 (120) N –
rs237885 (120) N –
rs237887 (120) N –
rs237889 (120) N –
rs237894 (120) N –
rs237897 (120) N –
rs237899 (120) N –
rs4686301 (120) N –
rs9840864 (120) N –
PLAA rs7045881 (127) N –
(Continued)
TABLE 9 | Continued
Polymorphism Study Significant
findings
(N or Y)
Association with
good response to
clozapine (unless
stated otherwise)
RELN rs7341475 (127) N –
SHISA9 rs7192086 (127) N –
SLC1A1 rs2228622 (127) N –
SLC6A2 rs5569 (127) Y G allele
rs2242446 (127) N –
SLC6A3 30-bp VNTR in
intron 8
(50) N –
40-bp VNTR in the
3
′
-region
(50) N –
rs2652511 (50) N –
T-844C (127) N –
rs27072 (50) N –
rs2963238
(A1491C)
(50) N –
(127) –
rs2975226 (T-71A) (50) Y T allele
TCF4 rs9960767 (127) Y A allele
rs17594526 (127) N –
TNF −308G/A (126) N –
(91) N –
(129) Y A allele
TNIK rs2088885 (127) Y A allele
UGT1A3 rs10929302 (54) N –
rs28898605 (54) N –
rs28934877 (54) N –
rs3732218 (54) N –
rs3732220 (54) N –
rs3806591 (54) N –
rs3806595 (54) N –
rs4124874 (54) N –
rs4148323 (54) N –
rs869283 (54) N –
rs887829 (54) N –
*Hwang et al. (89) used a subset of the Hwang et al. (88) sample so results for the same
polymorphisms from the 2006 paper have not been reported, aResult only in European
samples.
performed by independent research groups (30, 97), though two
separate studies by two other research groups have found no
association (54, 101).
DISCUSSION
Since 1992, ninety-eight published studies have tested biological
predictors of symptomatic response to clozapine. While this
highlights the potential clinical importance of identifying good
clozapine responders in advance of starting treatment, these
25 years of research have failed to produce biomarkers with
sufficient accuracy for clinical decision making. The most
consistent findings are that a good response to clozapine
is associated with greater structural integrity and activity in
prefrontal cortical areas, possibly reflecting less severe brain
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TABLE 10 | Significant findings for haplotypes.
Gene Alleles Study Association
DRD1 rs265981-T
rs4532-G
rs686-A
(90) Responsea
rs265981-T
rs4532-G
rs686-G
(90) Responseb
DRD2 rs1125394-A
rs1079598 (TaqIB)-T
Taq1A-C
(88) Responseb
rs1079598 (TaqIB)-T
Taq1D-T
NcoI-C
(88) Responsea
Taq1D-T
NcoI-C
C957T-T
(88) Responsea
−141 Ins
rs4648317-C
rs1125394-A
(88) Responseb
rs4648317-C
rs1125394-A
rs1079598 (TaqIB) - T
(88) Responseb
rs1125394-A
rs1079598 (TaqI B) - T
Taq1D-T
(88) Responseb
rs2242592-C
rs2242593-A
Taq1A-C
(88) Responseb
rs1125394-A
rs1079598 (TaqIB)-T
(89) Responseb
rs4648317-C
rs1125394-A
rs1079598 (TaqIB)-T
(89) Responseb
rs1125394-A
rs1079598 (TaqIB) - T
rs1800498 (TaqID) - C
(89) Responseb
DRD3 rs6280-A
rs167770-C
rs2134655-G
(91) Non-responsea
rs6280-A
rs167770-C
(91) Non-responsea
rs6280-A
rs167770-T
(91) Responsea
rs905568-C
rs2399504-A
rs7611535-A
(91) Responsea
rs7611535-G
rs6762200-G
rs1394016-C
(91) Responseb
rs6762200-A
rs1394016-T
rs6280-G
(91) Responseb
rs6762200-G
rs1394016-C
rs6280-G
(91) Responseb
rs1394016-C
rs6280-G
rs167770-C
(91) Responsea
(Continued)
TABLE 10 | Continued
Gene Alleles Study Association
rs7611535-G
rs6762200-G
rs1394016-T
(91) Non-responsea
rs7611535-A
rs6762200-A
rs1394016-C
(91) Non-responseb
rs167770-C
rs2134655-G
(91) Non-responsea
rs7611535-A
rs6762200-A
(91) Non-responseb
rs2399504-G
rs7611535-G
(91) Responseb
rs6762200-G
rs1394016-T
rs6280-G
(91) Responseb
FKBP5 rs3777747-A
rs1360780-T
rs17542466-A
rs2766533-G
(43) Non-response
GFRA2 rs1128397-T
rs13250096-G
rs4567028-G
(119) Response
HTR3A rs2276302-A
rs1062613-C
rs1150226-C
(118) Response
NTRK2 rs1619120-G
rs1778929-T
rs10465180-C
(43) Non-response
rs1619120-G
rs1778929-C
rs10465180-T
(43) Response
aResult only in White participants, bResult only in African-American participants.
pathophysiology than in poor responders, and a lower ratio
of the dopamine metabolite HVA to the serotonin metabolite
5-HIAA in CSF before clozapine initiation, reflecting higher
serotonergic compared to dopaminergic turnover. However,
there have been relatively few studies investigating these
biomarkers prospectively and further replication is required.
Regarding prefrontal cortical areas, prospective studies have
found consistent evidence that higher prefrontal cortical volumes
before clozapine initiation are directly associated with a greater
degree of symptomatic response to clozapine (31, 36, 37), with
some suggestion of specificity to improvements in negative
symptom severity (31, 37). Studies examining perfusion or
metabolism have similarly associated higher levels of prefrontal
activity with a higher degree of symptomatic response (32,
37, 41). These results are consistent with the majority, but
not all (132) of cross-sectional studies finding that clozapine
responders have higher prefrontal cortical volumes than non-
responders (25, 27, 28). In addition, some evidence indicates
that integrity/activity of the thalamus may also be important
in predicting clozapine response (32, 37, 41). Importantly, the
jack-knifed classification of Rodriguez et al. (41) using DLPFC
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TABLE 11 | Significant gene-gene interaction results.
Genes Polymorphisms Study
DRD1; DRD3 rs686; Ser9Gly (92)a
rs4532;
rs1394016
(92)a
DRD2; DRD3 Taq1b;
rs2134655
(92)a
C975T; Ser9Gly (92)b
DRD1; GRIN2A rs265976;
GTrepeat
(92)b
GFRA1; GFRA2;
GFRA3
rs10885888;
rs4237073;
rs7726580
(119)
HTR2A; HTR2A;
HTR2C; HTR2C;
SLC6A4; HRH1
T102C;
His452Tyr;
G-330T /
C-244T repeat;
Cys23Ser;
HTTLPR;
G-1018A
(76)
HTR2A;
ADRA1A;
ADRA2A;
ADRB3; GNB3;
plus clinical
information in
artificial neural
network
T102C;
Arg347Cys;
−1291C>G;
Trp64Arg;
825C>T
(101)
aResult only in White participants, bResult only in African-American participants.
and thalamic activity correctly identified 78.9% cases according
to clozapine response, and the effect size of the difference in
prefrontal sulcal widening score between clozapine responders
and non-responders reported by Konicki et al. (36) can be
calculated as a large effect size of d = 3.8.
It is unclear whether prefrontal structural integrity or
activity may be predictive of clozapine response specifically,
or whether prefrontal integrity is non-specifically prognostic
of outcome. Findings relating prefrontal volume to symptom
outcomes in non-clozapine treated patients are mixed (37, 133–
135), with the largest study finding no relationships between
gray matter volume at illness onset and outcome 2 years
later (135). Some studies indicate that clozapine has greater
ability to modulate prefrontal activity than other antipsychotic
compounds (29, 109, 136–138), but we are not aware of any
studies that have specifically compared the ability of prefrontal
cortical variables to predict response to clozapine vs. other
antipsychotics. Determination of treatment specificity would
be important for clinical decision-making around clozapine
initiation.
The other most replicated finding is that the ratio of the
dopamine to serotonin metabolites HVA:5-HIAA in CSF at
baseline predicted clozapine response (47, 48, 64). Where
available, the effect sizes calculated for these studies are large
[d = 0.8 (47) and 1.2 (48)]. CSF HVA and 5-HIAA respectively
reflect brain dopaminergic and serotonergic turnover, with some
evidence that lumbar CSF HVA is primarily from the striatum
(139) and 5-HIAA from the frontal cortex (47). These findings
in the absence of predictive value of CSF HVA or 5-HIAA alone
suggest that the dopamine-serotonin balance is predictive of
clozapine response. One report that CSF HVA/5-HIAA ratio was
not predictive of response to olanzapine (140) may be suggestive
of clozapine specificity, although further confirmation is
needed.
In terms of genetic predictors of clozapine response,
our results highlight the overall inability of candidate gene
approaches to reproducibly predict clozapine response. Of
the 379 polymorphisms investigated in relation to clozapine
response, replication by two or more independent research
groups is only available for the DRD3 Ser9Gly (113, 115), HTR2A
His452Tyr (73, 74, 76, 106), 5HTT rs25531 (76, 98), and C825T
GNB3 (30, 97) polymorphisms. Furthermore, findings of no
association with clozapine response were also reported for DRD3
(76, 77, 91, 104, 109), HTR2A His452Tyr (44, 102), C825T
GNB3 (54) and no findings were replicated by more than two
independent groups. However, as is the case for schizophrenia,
clozapine response is unlikely to be dictated by a single gene
variant, and more likely reflects additive or interacting effects
at multiple genetic loci. One study investigating a combination
of six polymorphisms predicted clozapine response with the
retrospective positive predictive value of 76.7% and a sensitivity
of 95% (76) onwhich basis a pharmacogenetic test was developed,
although it is no longer available. Similarly, using an artificial
neural network to combine five polymorphisms with clinical data
retrospectively identified all clozapine responders and 76.5% of
non-responders (101).
Since many of these studies were done, technology has
advanced to genome-wide association studies (GWAS), which
take a hypothesis-free approach but require very large samples.
GWAS is being applied to identify polymorphisms contributing
to response to non-clozapine antipsychotics (141) and may be
applied to clozapine in the future. This approach is encouraged by
reports that polygenic risk scores for schizophrenia may associate
with the degree of clozapine response (83). However, genome-
wide approaches specifically comparing good vs. poor responders
to clozapine are required because many of the candidate gene
studies identified by our review investigated polymorphisms
previously associated with non-clozapine antipsychotic response
with minimal success or without replication [e.g., NRXN1:
(122); ABCB1: (54, 127)], indicating that clozapine research
would benefit from approaches able to identify novel genetic
associations. Another avenue to explore is epigenetic variation, in
the form of chemical modifications associated with differing gene
expression such as DNA or histone methylation, which may play
a role in clozapine response above and beyond genetic variation;
evidence indicates both that variation in these modifications is
associated with schizophrenia (142) and that clozapine induces
changes in these modifications (143).
Our review also highlights several methodological
considerations for future studies examining predictive
biomarkers of clozapine response. First, there are overall
relatively few studies that have prospectively examined non-
genetic biological predictors of clozapine response despite
their potential clinical importance. This likely reflects several
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practical factors. In our own experience, patients who are about
to start clozapine can be difficult to recruit to research involving
neuroimaging or invasive procedures, because they are often very
unwell and may lack capacity to consent. Additionally, research
participation needs to be approached and timed carefully around
clinical conversations regarding clozapine initiation. This may
partly explain the relatively few studies overall, and small sample
sizes in some studies.
Secondly, although a response to clozapine will require
adequate dosing, only nine of the ninety-eight studies included
in our review reported clozapine plasma concentrations.Without
this information it is not possible to determine the extent
to which poor response may reflect sub-therapeutic plasma
clozapine concentrations rather than clozapine inefficacy. There
was also significant variability in criteria used to determine
clozapine response/non-response as well as variability in
clozapine treatment duration. Clinical trials indicate that the
majority of patients who will respond to clozapine will do so
in the first 6 weeks of treatment, which is associated with
∼30% response (57, 144). By 12 weeks of clozapine treatment,
a response is seen in 40–50% of patients (145, 146). Therefore,
studies of less than 12 weeks duration may have been too
short to establish clozapine response or non-response. To
address some of this inconsistency, the Treatment Response and
Resistance in Psychosis (TRRIP) Working Group have recently
provided consensus guidelines for determining and reporting
adequate treatment and treatment response (11); this includes
a recommendation that clozapine therapy be maintained for a
minimum of 3months after therapeutic plasma levels are reached
before determining response.
As with other biomarker research, technical constraints,
and cost may impede the translation of some markers to
clinical practice. Broadly, blood-based biomarkers may be
more readily implemented than biomarkers requiring advanced
neuroimaging techniques, lumbar puncture or specialized
analysis. However, this should be balanced against the high
economic costs of treatment resistant schizophrenia. Models
based on clinical or demographic factors may be easier to
implement. However, as for biological markers, previous reviews
of clinical predictors of clozapine response have failed to identify
any with “adequate reproducibility, sensitivity and specificity
for clozapine,” instead suggesting that a combination of factors
may be most fruitful (24). Another broader challenge is the
lack of established biological underpinnings for schizophrenia
and the subsequent heterogeneity in patients, which may
obscure identification of biological predictors. Research indicates
potential categorical differences between patients with treatment-
responsive and treatment-resistant schizophrenia (12), as well
as potential sub-groups within treatment-resistant patients
(21), with further sub-groups likely. Such differences may
contribute to the lack of reproducible research findings,
and future research could explore whether predictors of
outcome are specific to sub-groups within the schizophrenia
diagnosis.
In conclusion, this review supports the notion that biological
measures might be useful in predicting response to clozapine,
and that higher prefrontal structural integrity and activity
and lower ratios of HVA/5-HIAA in CSF may be associated
with a better response. Future research should confirm these
findings, investigate treatment-specificity, and apply genome-
wide approaches. If these approaches are to aid clinical decision
making, future studies will also need to address the accuracy
of prediction at the individual patient level, which may be
facilitated by statistical models combining neuroimaging, CSF-
based, blood-based, genetic, clinical, or demographic measures.
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